[Shi4 Pharmaceutical Group: Letermovir Injection received drug production registration approval] On September 10th, Shi4 Pharmaceutical Group issued a voluntary announcement that the company has obtained the drug production registration approval document from the China National Medical Products Administration for Letermovir Injection (12ml:240mg). This product belongs to Category 4 chemical drugs and is deemed to have passed the consistency evaluation. Letermovir injection is mainly used for cytomegalovirus (CMV) seropositive adult recipients who have received allogeneic hematopoietic stem cell transplantation to prevent cytomegalovirus infection and cytomegalovirus disease. It needs to be used in combination with basic infusion and should be used in the perioperative period of hematopoietic stem cell transplantation. Relying on the existing advantages of basic infusion, the Group continues to improve the therapeutic injection product pipeline, and this approval further enriches the perioperative product portfolio.